Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone ER vs oxycodone ER for moderate to severe cancer pain
ChiCTR2500112916Phase 3Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromorphone in cancer pain (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Change in the rating for the most severe pain in the past 24 hours, Change in the average severity score of pain over the past 24 hours and 6 more. Started Nov 2025; status: completed.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2500112916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112916.